 Blackstone, Bain Capital and Taisho Pharmaceutical are among the final bidders for Takeda Pharmaceuticals 4502.T consumer drug business in Japan, a deal that could be worth up to 400 billion yen 3.7 billion, three people familiar with the deal said. 